Discovery and Characterization of Novel BLIMP‑1 Heterobifunctional Ligand-Directed Degraders

B-lymphocyte-induced maturation protein 1 (BLIMP-1/PRDM1) is a master transcriptional repressor essential for terminal differentiation of activated B-cells into bone-marrow resident plasma cells. Multiple myeloma (MM) is a plasma cell malignancy wherein the BLIMP-1 regulon remains critical to suppor...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Bryan J. Simmons (22676881) (author)
Další autoři: Lynda Groocock (18218650) (author), Jesus Moreno (1312926) (author), David S. Peters (9079778) (author), Meredith E. Hughes (8822891) (author), Vijay Veeravalli (17374410) (author), Jennifer M. Crawford (1453204) (author), Matthew Chalkley (22676884) (author), Mark Griffith (22676887) (author), Melissa Plooster (22676890) (author), Bo Hu (126105) (author), Jim Gamez (22384825) (author), Jim Leisten (1562386) (author), Michael J. Barnes (22676893) (author), Jason Chinn (2500474) (author), Gauri Deb (3625370) (author), Hardik Modi (22676896) (author), Madhu Katepalli (22676899) (author), Dahlia Weiss (22384834) (author), Walter Won (22676902) (author), Zhenghang Sun (19474606) (author), Shan Yu (219591) (author), Cameron Reid (22676905) (author), Andrew F. Donnell (1893616) (author), Ling Li (38566) (author), Edmond R. Watson (19198701) (author), Sophie Perrin-Ninkovic (15067518) (author), Lihong Shi (481066) (author), Rama Krishna Narla (1562347) (author), Christoph W. Zapf (2019895) (author), Neil Bence (720479) (author), Antonia Lopez-Girona (8596584) (author), Jennifer R. Riggs (1278165) (author)
Vydáno: 2025
Témata:
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:B-lymphocyte-induced maturation protein 1 (BLIMP-1/PRDM1) is a master transcriptional repressor essential for terminal differentiation of activated B-cells into bone-marrow resident plasma cells. Multiple myeloma (MM) is a plasma cell malignancy wherein the BLIMP-1 regulon remains critical to support basal cell functions, such as an elevated metabolic state and immunoglobulin production that underlie disease manifestation and tumor cell proliferation. It is predicted that perturbation of BLIMP-1 will significantly impact tumor cell homeostasis and ultimately reduce MM cell survival. Herein, we describe the discovery and optimization of the first orally bioavailable BLIMP-1 heterobifunctional ligand-directed degrader (LDD) and demonstration of the expected antitumor response and immunomodulatory biology following BLIMP-1 degradation using preclinical in vivo MM models.